Streptozotocin (STZ) is an antibiotic often used in the treatment of different types of cancers. It is also highly cytotoxic to the pancreatic beta-cells and therefore is commonly used to induce experimental type 1 diabetes in rodents. Resistance towards STZ-induced cytotoxicity in cancer cells has also been reported. Our previous studies have reported organ-specific toxicity and metabolic alterations in STZ-induced diabetic rats. STZ induces oxidative stress and metabolic complications. The precise molecular mechanism of STZ-induced toxicity in different tissues and carcinomas is, however, unclear. We have, therefore, investigated the mechanism of cytotoxicity of STZ in HepG2 hepatoma cells in culture. Cells were treated with different doses of STZ for various time intervals and the cytotoxicity was studied by observing the alterations in oxidative stress, mitochondrial redox and metabolic functions. STZ induced ROS and RNS formation and oxidative stress as measured by an increase in the lipid peroxidation as well as alterations in the GSH-dependent antioxidant metabolism. The mitochondria appear to be a highly sensitive target for STZ toxicity. The mitochondrial membrane potential and enzyme activities were altered in STZ treated cells resulting in the inhibition of ATP synthesis. ROS-sensitive mitochondrial aconitase activity was markedly inhibited suggesting increased oxidative stress in STZ-induced mitochondrial toxicity. These results suggest that STZ-induced cytotoxicity in HepG2 cells is mediated, at least in part, by the increase in ROS/RNS production, oxidative stress and mitochondrial dysfunction. Our study may be significant for better understanding the mechanisms of STZ action in chemotherapy and drug induced toxicity.
References
[1]
Weiss, R.B. Streptozotocin: A review of its pharmacology, efficacy, and toxicity. Cancer Treat. Rep 1982, 66, 427–438.
[2]
Dolan, M.E. Inhibition of DNA repair as a means of increasing the antitumor activity of DNA active agents. Adv. Drug Del. Rev 1997, 26, 105–118.
[3]
Lewis, C.; Barbiers, A.R. Streptozotocin, a new antibiotic. In vitro and in vivo evaluation. Antibiot. Ann 1959, 7, 247–254.
[4]
Schroy, P.C., III; Cohen, A.; Winawer, S.J.; Friedman, E.A. New chemotherapeutic drug sensitivity assay for colon carcinomas in monolayer culture. Cancer Res 1988, 48, 3236–3244.
[5]
Van Dyke, K.; Jabbour, N.; Hoeldtke, R.; van dyke, C.; van dyke, M. Oxidative/nitrosative stresses trigger type I diabetes: Preventable in streptozotocin rats and detectable in human disease. Ann. N. Y. Acad. Sci 2010, 1203, 138–145.
[6]
LeDoux, S.P.; Woodley, S.E.; Patton, N.J.; Wilson, G.L. Mechanisms of nitrosourea-induced beta-cell damage. Alterations in DNA. Diabetes 1986, 35, 866–872.
[7]
Capucci, M.S.; Hoffmann, M.E.; Natarajan, A.T. Streptozotocin-induced genotoxic effects in Chinese hamster cells: The resistant phenotype of V79 cells. Mutat. Res 1995, 347, 79–85.
[8]
Ridolfi, R.; Amaducci, L.; Derni, S.; Fabbri, L.; Innocenti, M.P.; Vignutelli, P. Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: Experience with 13 patients. J. Chemother 1991, 3, 328–331.
[9]
Islam, M.S.; Loots du, T. Experimental rodent models of type 2 diabetes: A review. Methods Find Exp. Clin. Pharmacol 2009, 31, 249–261.
[10]
Wei, L.; Lu, Y.; He, S.; Jin, X.; Zeng, L.; Zhang, S.; Chen, Y.; Tian, B.; Mai, G.; Yang, G.; et al. Induction of diabetes with signs of autoimmunity in primates by the injection of multiple-low-dose streptozotocin. Biochem. Biophys. Res. Commun 2011, 412, 373–378.
[11]
Hosokawa, M.; Dolci, W.; Thorens, B. Differential sensitivity of GLUT1 and GLUT2-expressing beta cells to streptozotocin. Biochem. Biophys. Res. Commun 2001, 289, 1114–1117.
[12]
Friederich, M.; Hansell, P.; Palm, F. Diabetes, oxidative stress, nitric oxide and mitochondria function. Curr. Diabetes Rev 2009, 5, 120–144.
[13]
Simmons, R.A. Developmental origins of diabetes: The role of oxidative stress. Free Radic. Biol. Med 2006, 40, 917–922.
[14]
Raza, H.; Prabu, S.K.; Robin, M.A.; Avadhani, N.G. Elevated Mitochondrial cytochrome P450 2E1 and Glutathione S-transferase A4–4 in streptozotocin-induced diabetic rats: Tissue-specific variations and role in oxidative stress. Diabetes 2004, 53, 185–194.
[15]
Raza, H.; Subbuswamy, K.P.; John, A.; Avadhani, N.G. Impaired mitochondrial respiratory functions and oxidative stress in streptozotocin-induced diabetic rats. Int. J. Mol. Sci 2011, 12, 3133–3147.
[16]
Van Dyke, K.; Ghareeb, E.; van Dyke, M.; Sosa, A.; Hoeldtke, R.D.; van Thiel, D.H. Luminescence experiments involved in the mechanism of streptozotocin diabetes and cataract formation. Luminescence 2008, 23, 386–391.
[17]
Liu, H.K.; McCluskey, J.T.; Mc Clenghan, N.H.; Flatt, P.R. Streptozotocin-resistant BRIN-BD11 cells possess wide spectrum of toxin tolerance and enhanced insulin-secretory capacity. Endocrine 2007, 32, 20–29.
[18]
Tuch, B.E.; Beynon, S.; Tabiin, M.T.; Sassoon, R.; Goodman, R.J.; Simpson, A.M. Effect of beta-cell toxins on genetically engineered insulin-secreting cells. J. Autoimmun 1997, 10, 239–244.
[19]
Saini, K.S.; Thompson, C.; Winterford, C.M.; Walker, N.I.; Cameron, D.P. Streptozotocin at low doses induces apoptosis and at high doses causes necrosis in a murine pancreatic β-cells line, INS-1. Biochem. Mol. Biol. Int 1996, 39, 1229–1236.
[20]
Harel, A.; Bloch, O.; Vardi, P.; Bloch, K. Sensitivity of HaCat keratinocytes to diabetogenic toxins. Biochem. Pharmacol 2002, 63, 171–178.
[21]
Koo, K.B.; Suh, H.J.; Ra, K.S.; Choi, J.W. Protective effect of cyclo(his-pro) on streptozotocin-induced cytotoxicity and apoptosis in vitro. J. Microbiol. Biotechnol 2011, 21, 218–227.
[22]
Latha, M.; Pari, L.; Sitasawad, S.; Bhonde, R. Scoparia dulcis, a traditional antidiabetic plant, protects against streptozotocin induced oxidative stress and apoptosis in vitro and in vivo. J. Biochem. Mol. Toxicol 2004, 18, 261–272.
[23]
Locke, M.; Anderson, J. NF-κB activation in organs from STZ-treated rats. Appl. Physiol. Nutr. Metab 2011, 36, 121–127.
[24]
Kim, E.K.; Song, M.Y.; Kim, I.S.; Moon, W.S.; Ryu, D.G.; So, H.S.; Park, R.; Park, J.W.; Kwon, K.B.; Park, B.H. Beneficial effect of Flos magnoliae extract on multiple low dose streptozotocin-induced type 1 diabetes development and cytokine-induced β-cell damage. Int. J. Mol. Med 2008, 22, 481–488.
[25]
Bathaie, S.Z.; Sedghgoo, F.; Jafarnejad, A.; Farzami, B.; Khayatian, M. Spectroscopic studies of STZ-induced methylated-DNA in both in vivo and in vitro conditions. Spectrochim. Acta A Mol. Biomol. Spectrosc 2008, 71, 803–808.
[26]
Bolzán, A.D.; Bianchi, M.S. Genotoxicity of streptozotocin. Mutat. Res 2002, 512, 121–134.
[27]
Raza, H.; John, A.; Benedict, S. Acetylsalicylic acid-induced oxidative stress, cell cycle arrest, apoptosis and mitochondrial dysfunction in human hepatoma HepG2 cells. Eur. J. Pharmacol 2011, 668, 15–24.
[28]
Raza, H.; John, A.; Brown, E.M.; Benedict, S.; Kambal, A. Alterations in mitochondrial respiratory functions, redox metabolism and apoptosis by oxidant 4-hydroxynonenal and antioxidants curcumin and melatonin in PC12 cells. Toxicol. Appl. Pharmacol 2008, 226, 161–168.
[29]
Birch-Machin, M.A.; Turnbull, D.M. Assaying mitochondrial respiratory complex activity in mitochondria isolated from human cells and tissues. Methods Cell Biol 2001, 65, 97–117.
[30]
Spear, J.F.; Prabu, S.K.; Galati, N.; Raza, H.; Anandatheerthavarada, H.K.; Avadhani, N.G. β1-adrenoreceptor activation contributes to ischemia-reperfusion damage as well as playing a role in ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol 2007, 292, H2459–H2466.
[31]
Laemmli, U.K. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970, 227, 680–685.
[32]
Towbin, H.; Staehelin, T.; Gordon, J. Electrophoresis transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76, 4350–4354.
